Compare AIRG & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRG | CGEN |
|---|---|---|
| Founded | 1995 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.3M | 270.4M |
| IPO Year | 2016 | 2001 |
| Metric | AIRG | CGEN |
|---|---|---|
| Price | $7.08 | $2.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $6.25 | $5.00 |
| AVG Volume (30 Days) | 115.8K | ★ 502.5K |
| Earning Date | 05-06-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,779,000.00 | N/A |
| Revenue This Year | $10.31 | N/A |
| Revenue Next Year | $20.71 | $75.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.00 | $1.30 |
| 52 Week High | $7.39 | $3.24 |
| Indicator | AIRG | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 41.40 |
| Support Level | $3.93 | $1.46 |
| Resistance Level | $7.39 | $3.14 |
| Average True Range (ATR) | 0.38 | 0.18 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 71.08 | 2.50 |
Airgain Incs a provider of advance wireless connectivity solutions. It is focused on delivering high-performance, cost-effective, and energy-efficient wireless solutions that enable rapid market deployment. It mission is to connect the world through integrated, and optimized wireless solutions. Companies' diverse product portfolio serves three primary markets: enterprise, automotive, and consumer. While historically recognized for high-performance radio frequency (RF) components, Airgain is increasingly delivering integrated, system-level connectivity solutions that combine hardware, software, and cloud management. The enterprise market demands reliable wireless access across diverse settings, including smart cities, campuses, stadiums, transportation hubs, utilities, buildings suburbs.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.